

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SE

03 AUG 14 PM 4

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) -All Filers Are Required to Complete This Page

1. Registrant Name PodestaMattoon			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 1001 G Street, NW Suite 900 East City Washington State/Zip (or Country) DC 20001			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Tom Bianchetti	Telephone 393-1010	E-mail (optional) bianchetti@podesta.com	5. Senate ID # 31680-238
7. Client Name <input type="checkbox"/> Self Genzyme			6. House ID # 31110-007

TYPE OF REPORT 8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____

11. No Lobbying Activities

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$60,000.00</u> Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate the accounting method. See instructions for description of method.</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(c) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature *Claudia James* Date 8/14/2003

Printed Name and Title Claudia James - President Page

Registrant Name: PodestaMattoon

Client Name: Genzyme

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

17. House(s) of Congress and Federal agencies contacted

Check if None

Executive Office of the President

HHS

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Clark, Bill	Executive Office of the POTUS-Office of Personnel
James, Claudia	
Maddox, Lauren	
Mantz, Jonathan	
Mattoon, Daniel J.	
Podesta, Anthony	
Siciliano, Jen	Dir. of Communications, Senate Appropriations Com

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date **8/14/2003**

Printed Name and Title **Claudia James - President** _____ Page

Registrant Name: PodestaMattoonClient Name: Genzyme

Item	Description	Data
16	Lobbying Issues	<p>H.R.1298, Orphan Drug Tax Credit Act of 2001.</p> <p>S.1304, A bill to amend title XVIII of the Social Security Act to provide for coverage under the medicare program of oral drugs to reduce serum phosphat levels in dialysis patients with end-stage renal disease.</p> <p>H.R.3246, A bill to amend title XVIII of the Social Security Act to provide for coverage under the medicare program of oral drugs to reduce serum phosphat levels in dialysis patients with end-stage renal disease.</p> <p>S.1341, A bill to amend the Internal Revenue Code of 1986 to expand human clinical trials qualifying for the orphan drug credit, and for other purposes.</p> <p>Appointment of FDA Commissioner.</p> <p>Medicare hospital outpatient reimbursement issues.</p>

